statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD - Get Free Report)'s stock price traded up 1.7% on Friday . The company traded as high as $2.45 and last traded at $2.39. 32,983 shares traded hands during...

MyMD Pharmaceuticals (NASDAQ:MYMD) Trading 1.7% Higher

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MyMD Pharmaceuticals regains compliance with Nasdaq

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and...

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

MyMD Pharmaceuticals trading halted, news pending

MyMD Pharmaceuticals announces 1-for-30 reverse stock split

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD  Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest...

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Short Interest Update

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.

MyMD Pharmaceuticals Inc

Volume	14,790.00
52-Wk High	$70.50
52-Wk Low	$2.00

MYMD MyMD Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community